Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

(2010) Luis Paz-Ares et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer

(2010) Tony Mok et al.   Journal of Thoracic Oncology

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

(2010) Yosuke Togashi et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?

(2009) E. Vasile et al.   ANNALS OF ONCOLOGY

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

(2009) Tatsuya Katayama et al.   Journal of Thoracic Oncology

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

(2009) Jeong-Eun Kim et al.   LUNG CANCER

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

(2009) Kyoichi Kaira et al.   LUNG CANCER

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment

(2008) D. H. Lee et al.   ANNALS OF ONCOLOGY